Current clinical practice of Botulinum toxin A treatment in the lower extremities in children with cerebral palsy in Sweden – a population-based registry study

<p>To describe current lower-extremity Botulinum toxin A (BTX-A) treatment in children with cerebral palsy (CP) in Sweden and compare treatment patterns in 2023–2024 with published nationwide data from 2014–2015.</p> <p>This retrospective registry study included 3,216 children aged 1–15 years registered in the Swedish CP follow-up program and national quality registry (CPUP) in 2023–2024. BTX-A treatment was analyzed in relation to age, sex, Gross Motor Function Classification System (GMFCS) level, CP subtype, and injected muscle groups.

Logistic regression and chi-square tests were used.</p> <p>BTX-A treatment of the lower extremities was reported for 828 children (26%). Treatment was most common at 7–9 years of age (33%) and among children at GMFCS levels III (38%) and IV (40%). Bilateral spastic CP had the highest treatment rate among CP subtypes (39%).